Memory clinic patients were administered the MoCA, MMSE, and a comprehensive formal neuropsychological battery. 4 key findings →
Participants: 36 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
As the population ages, it is increasingly important to use effective short cognitive tests for suspected dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Chronic kidney disease (CKD) patients undergoing hemodialysis (HD) therapy have an increased risk of developing cognitive impairment and dementia, which are known relevant factors in disease prognosis and therapeutic success, but still lack adequate screening in clinical routine. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
All versions of the Montreal Cognitive Assessment (MoCA) lack population-based data of 80-plus individuals. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
49/100
Given that aging is associated with higher risk of cognitive decline and dementia, improving early detection of cognitive impairment has become a research and clinical priority. 4 key findings →
Participants: 200 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Acute cognitive impairment and delirium occur after major stroke and are associated with poor cognitive outcome. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cognitive deficits are commonly observed in stroke patients. 4 key findings →
Participants: 194 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Clinicians and researchers who measure cognitive dysfunction often use the Alzheimer's Disease Assessment Scale--Cognitive Subscale (ADAS-Cog), the Mini-Mental State Examination (MMSE), or the Clinical Dementia Rating scale (CDR-SOB). 4 key findings →
Participants: 1,709 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The AB Cognitive Screen (ABCS) 135, sensitive in differentiating MCI from dementia, was modified to improve sensitivity and specificity, producing the quick mild cognitive impairment (Qmci) screen. 4 key findings →
Participants: 630 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Several reviews have summarized the prevalence of dementia in mainland China, Hong Kong and Taiwan. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Astrocytic injury and endothelial activation are interconnected processes within the neurovascular system that may contribute to variability in cognitive performance among cognitively unimpaired adults. 3 key findings →
Design: cross-sectional Participants: 313 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study utilized an initial dataset of 188,700 participant records from NACC. 5 key findings →
Participants: 16,309 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This comprehensive review examines the integration of Quantitative Electroencephalography (qEEG) and Artificial Intelligence (AI) in the detection and diagnosis of Alzheimer's Disease (AD). 5 key findings →
Participants: 890 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
49/100
The proportion of false negatives from FDG-PET ranged from 11-55%. 5 key findings →
Design: longitudinal study Participants: 112 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 394 participants, 35 % had preoperative CI on the MoCA, 15 % on the AD8, and 12 % on the Mini-Cog. 5 key findings →
Participants: 394 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
CDR-SB and MoCA scores showed strong inverse correlation (Spearman's ρ = -0.68; p < 0.001). 3 key findings →
Design: cross-sectional Participants: 23,717 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Early identification of individuals at increased risk of mild cognitive impairment (MCI), a pre-dementia state, can provide a critical window for prompt intervention to prevent or reverse disease progression. 5 key findings →
Design: longitudinal study Participants: 87 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 110 patients were identified. 5 key findings →
Participants: 110 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In this retrospective, confounder-adjusted study, anticoagulation was associated with slower cognitive/functional decline and lower hospitalization/mortality risk in AF and dementia patients. 3 key findings →
Design: cohort study Participants: 291 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
During follow-up, cholinergic WMHV was associated with an annual decline of Mini-Mental State Examination (MMSE) (β coefficient, -0.239; P = 0.004), and incident dementia (HR = 3.54; 95%CI: 2.05-6.10). 5 key findings →
Design: cross-sectional Participants: 751 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Synaptic degeneration has been linked to cognitive decline. 5 key findings →
Participants: 187 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This report summarizes the consensus recommendations of a panel of neuropathologists from the United States and Europe to improve the postmortem diagnostic criteria for Alzheimer’s disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Mini-Mental State (MMS) examination is a widely used screening test for dementia. 1 key finding →
Participants: 249 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We conducted a comprehensive screening of rare coding variants in an African American cohort to identify novel pathogenic mutations within the early-onset Alzheimer's disease (EOAD) genes (APP, PSEN1, and PSEN2) in this understudied population. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
[18F]flutemetamol PET scans were positive in 133 out of 211 (63%) patients, of whom 110 out of 144 (76%) patients had a pre-PET Alzheimer's disease (AD) diagnosis and 23 out of 67 (34%) patients had a non-AD diagnosis. 5 key findings →
Participants: 211 Evidence: low
Full summary, score breakdown and related studies → Original source
From across this tag
10 of the 1,775 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set
- Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
- Obesity and impaired cognitive functioning in the elderly: a population-based cross-sectional study (NEDICES)
- Wearable technological platform for multidomain diagnostic and exercise interventions in Parkinson's disease
- Benefits and Harms of Dementia Screening for Family Members of Older Adults: A Randomized Clinical Trial
- Cognitive Screening Beliefs and Behaviors Among Older US Adults: Results from the National Poll on Healthy Aging
- Applicability of the CERAD neuropsychological battery to Brazilian elderly
- Community-Based Participatory Research on Art Engagement for People with Dementia in Japan
- Validation, Deployment, and Real-World Implementation of a Modular Toolbox for Alzheimer's Disease Detection and Dementia Risk Reduction: The AD-RIDDLE Project
- Construction of a microcavity-based microfluidic chip with simultaneous SERS quantification of dual biomarkers for early diagnosis of Alzheimer's disease
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →